[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Navy General Hospital, Beijing\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":446},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,20,0,[8,48,68,91,111,130,154,175,196,219,240,258,278,298,320,345,365,388,403,425],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100632311","burden-evaluated-active-therapy-for-af-using-continuous-wearables-beat-af-trial-100632311",false,"NCT07512037","Burden-Evaluated Active Therapy for AF Using Continuous Wearables BEAT-AF Trial","Inclusion Criteria:\n\n* Inpatients ≥18 years of age at admission;\n* Paroxysmal atrial fibrillation was diagnosed;\n* Own a smart phone and a smart watch and be able to operate them basically;\n* Before being enrolled, the average daily atrial fibrillation burden was calculated to be ≥ 4.59% based on monitoring through an intelligent wristwatch for at least 3 days;\n* The treatment status meets any of the following conditions:\n\n  1. If anticoagulation therapy is being administered, the treatment plan must be stable for at least 4 weeks;\n  2. If heart rate or rhythm control medications are being used, the treatment plan must be stable for at least 4 weeks;\n  3. Or no specific rhythm control treatment for atrial fibrillation is being received;\n* Sign the informed consent form\n\nExclusion Criteria:\n\n* Has an implanted pacemaker, implantable cardioverter-defibrillator or cardiac resynchronization therapy device.\n* There may be skin diseases, limb deformities or allergies that prevent the proper wearing of wearable devices on the upper limbs.\n* Having active mental disorders or cognitive impairments, as well as other conditions that result in lack of or restricted ability to act, and which, in the judgment of the researchers, make it impossible for the subject to comply with the trial protocol.\n* During pregnancy, lactation, or planning to become pregnant during the trial period.\n* At the same time, participate in other clinical trials that may interfere with the results of this study","ALL","18 Years",{"count":18,"type":19},3194,"ESTIMATED","INTERVENTIONAL",[22],"NA","Traditional AF classification (e.g., paroxysmal, persistent, permanent) relies largely on patient-reported symptoms and intermittent electrocardiographic monitoring, which cannot continuously or objectively reflect disease progression, nor effectively inform optimal intervention timing. Although \"AF burden\" (i.e., duration of AF episodes) has emerged as a potential marker, its association with clinical outcomes remains inconsistent due to limitations in monitoring methods and its one-dimensional nature. Based on our previous work, investigators developed a five-dimensional AF progression model using photoplethysmography (PPG) signals collected from wearable devices. This model quantifies AF progression across five domains: episode frequency, duration, temporal aggregation, circadian rhythm, and tachycardia burden, enabling continuous and multidimensional assessment. Prior validation has demonstrated high agreement with 24-hour Holter monitoring and effective identification of high-risk patients.\n\nThe BEAT-AF trial is designed to evaluate the clinical utility of this model in a real-world setting. Specifically, investigators will investigate whether early intervention (e.g., optimization of medical therapy or consideration of catheter ablation) in patients with elevated five-dimensional AF burden (≥4.59%) can reduce symptoms, rhythm\u002Frate-related abnormalities, and AF-related adverse events (such as stroke and heart failure). This study is expected to provide new evidence for dynamic monitoring of AF progression, optimal timing of intervention, and personalized management strategies, ultimately improving patient outcomes.",[25,26,27],"Atrial Fibrillation (AF)","Digital Health Intervention","Wearable Monitoring",[29,30,31,32,33,34],"Atrial Fibrillation","AF Burden","Wearable Devices","Photoplethysmography (PPG)","Digital Health","Early Intervention","NOT_YET_RECRUITING","2026-03-30",{"date":38,"type":39},"2026-04-06","ACTUAL",{"date":41,"type":19},"2026-04",{"date":43,"type":19},"2029-03",{"name":45,"class":46},"Navy General Hospital, Beijing","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":54,"targetDuration":56,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":65,"leadSponsor":67,"locationsCount":4},"100631225","burden-evaluated-atrial-fibrillation-progession-and-thromboembolim-study-beat-af-te-study-100631225","NCT07497906","Burden-Evaluated Atrial Fibrillation Progession and ThromboEmbolim Study BEAT-AF TE Study","Inclusion Criteria:\n\n* (1) age ≥ 18 years; (2) confirmed diagnosis of atrial fibrillation (paroxysmal, persistent, or permanent); (3) ownership of a smartphone and a smartwatch, with the ability to perform basic operations; (4) provision of electronic informed consent.\n\nExclusion Criteria:\n\n* (1) presence of clear indications for anticoagulation therapy (e.g., mechanical heart valve, recent venous thromboembolism); (2) life expectancy \\\u003C 1 year; (3) severe cognitive impairment or psychiatric disorder; (4) known allergy to materials used in wearable devices; (5) concurrent participation in another clinical trial that may interfere with the outcomes of this study; (6) presence of an implanted pacemaker, implantable cardioverter-defibrillator, or cardiac resynchronization therapy device; (7) pregnancy, lactation, or planned pregnancy during the study period.",{"count":55,"type":19},10000,"12 Months","OBSERVATIONAL","This was a prospective, multicenter, observational cohort study. Patients with atrial fibrillation were consecutively recruited from the Cardiovascular Research Platform. After providing written informed consent, research assistants scheduled and assigned the patients to the participating centers of the BEAT-AF TE project according to their individual circumstances. Each center conducted follow-up management in accordance with the investigator's handbook, with a follow-up duration of 24 months. The patients were managed according to local clinical practice, and no study-related interventions were administered in this study; only follow-up data were recorded. This real-world data analysis aimed to investigate, based on the primary exposure variable (atrial fibrillation burden), primary outcome variables (ischemic stroke, systemic embolism, etc.), and secondary outcome variables (transient ischemic attack, hospitalization for heart failure, major bleeding events, all-cause mortality, etc.), whether there is a risk inflection point between atrial fibrillation burden and stroke, whether there is a reasonable threshold for the benefit of anticoagulation therapy, and whether there is a time-dependent risk of atrial fibrillation burden prior to stroke\u002Fthromboembolic events.",[25,60],"Atrial Fibrillation Burden","2026-03-23",{"date":63,"type":39},"2026-03-27",{"date":41,"type":19},{"date":66,"type":19},"2029-04",{"name":45,"class":46},{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":15,"minAge":75,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":20,"phases":78,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":4},"100607148","phase-2-g-pola-gemox-in-refractoryrelapsed-aggressive-b-cell-lymphoma-100607148","NCT07184788","G-Pola-GemOx in Refractory\u002FRelapsed Aggressive B-Cell Lymphoma","Glofitamab，Polatuzumab Vedotin and GemOx in Refractory\u002FRelapsed Aggressive B-Cell Lymphoma","Inclusion Criteria:\n\n* Pathologically confirmed Aggressive B-Cell Lymphoma (Including but not limited to diffuse large B-cell lymphoma, mantle cell lymphoma, Burkitt lymphoma, high-grade B-cell lymphoma, etc. according World Health Organization (WHO) classification;\n* Patient is ≥ 18 years of age at the time of signing the informed consent form (ICF).\n* Patient must understand and voluntarily sign an ICF prior to any study-specific assessments\u002Fprocedures being conducted;\n* Patient is willing and able to adhere to the study visit schedule and other protocol requirements;\n* Patient has not received chemotherapy previously.\n* Anticipated life expectancy at least 3 months\n\nExclusion Criteria:\n\n* Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment.\n* Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy.\n* Pregnant or lactating women","14 Years",{"count":77,"type":19},80,[79],"PHASE2","The goal of this phase 2 trial is to test the safety and efficacy of G-Pola-GemOx as induction therapy in patients with Refractory\u002FRelapsed Aggressive B-Cell Lymphoma.",[82],"Aggressive B-Cell Lymphoma","2025-09-14",{"date":85,"type":39},"2025-09-22",{"date":87,"type":19},"2025-10-01",{"date":89,"type":19},"2031-10-01",{"name":45,"class":46},{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":15,"minAge":75,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":20,"phases":99,"briefSummary":100,"conditions":101,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":4},"100567210","phase-2-g-pola-zlp-in-diffuse-large-b-cell-lymphoma-100567210","NCT06665217","G-Pola-ZLP in Diffuse Large B-Cell Lymphoma","Glofitamab, Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma","Inclusion Criteria:\n\n* Pathologically confirmed Diffuse Large B Cell Lymphoma according World Health Organization (WHO) classification;\n* Patient is ≥ 18 years of age at the time of signing the informed consent form (ICF).\n* Patient must understand and voluntarily sign an ICF prior to any study-specific assessments\u002Fprocedures being conducted;\n* Patient is willing and able to adhere to the study visit schedule and other protocol requirements;\n* Patient has not received chemotherapy previously.\n* Anticipated life expectancy at least 3 months\n\nExclusion Criteria:\n\n* Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment.\n* Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy.\n* Pregnant or lactating women",{"count":77,"type":19},[79],"The goal of this phase 2 trial is to test the safety and efficacy of G-Pola-ZLP as induction therapy in patients with DLBCL.",[102],"Diffuse Large B-Cell Lymphoma","2025-08-13",{"date":105,"type":39},"2025-08-14",{"date":107,"type":19},"2025-09-24",{"date":109,"type":19},"2030-01",{"name":45,"class":46},{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":15,"minAge":75,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":20,"phases":118,"briefSummary":119,"conditions":120,"keywords":4,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":47},"100567148","phase-2-pola-zr2p-in-previously-untreated-dlbcl-100567148","NCT06664411","Pola-ZR2P in Previously Untreated DLBCL","Polatuzumab Vedotin, Zanubrutinib, Rituximab, Lenalidomide and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma",{"count":77,"type":19},[79],"The goal of this phase 2 trial is to test the safety and efficacy of Pola-ZR2P as induction therapy in patients with DLBCL.",[121],"Diffuse Large B-cell Lymphoma","RECRUITING",{"date":124,"type":39},"2025-08-19",{"date":126,"type":39},"2024-09-24",{"date":128,"type":19},"2030-12",{"name":45,"class":46},{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":20,"phases":140,"briefSummary":141,"conditions":142,"keywords":145,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":47},"100545448","smart-technology-facilitated-patient-centered-care-for-patients-with-pulmonary-thromboembolism-100545448","NCT06382038","Smart Technology Facilitated Patient-centered Care for Patients With Pulmonary Thromboembolism","Smart Technology Facilitated Patient-centered Care for Patients With Pulmonary Thromboembolism：A Multicenter, Randomized Controlled Trial","SmaPE","Inclusion Criteria:\n\n* Inpatients aged ≥18 years;\n* （2）PTE confirmed through imaging examinations, meeting at least one of the following criteria: a.Newly diagnosed PTE during the current hospitalization; b. Prior PTE with imaging evidence of residual thrombus.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Previous PTE combined with CTEPH;\n* Mental retardation or a combination of other serious illnesses that make them incapable of living on their own;\n* Inability to use smartphones, computer tablets and other smart devices;\n* Being pregnant or breastfeeding;\n* Have participated in similar trials or are undergoing other clinical trials.",{"count":139,"type":19},2972,[22],"Smart technologies, such as wearable devices, mobile technologies, and artificial intelligence, are being investigated for use in health management. These technologies have the potential to be applied in disease pre-warning, decision-making support, health education, and healthcare maintenance. They are expected to address the challenges in managing thrombosis, improve access to high-quality medical resources in various regions, and enhance the development of a network for thrombosis rescue and treatment prevention.\n\nThe objective of this study is to evaluate the impact of mobile venous thromboembolism application (mVTEA) based patient-centered management of pulmonary thromboembolism (PTE) on the long-term outcome of PTE patients, in order to enhance clinical practice and establish a foundation of evidence for managing patients with PTE.",[143,144,33],"Venous Thromboembolism","Pulmonary Thromboembolisms",[143,144,33],"2025-05-27",{"date":148,"type":39},"2025-05-31",{"date":150,"type":19},"2025-10-08",{"date":152,"type":19},"2026-10-31",{"name":45,"class":46},{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":160,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":161,"targetDuration":163,"studyType":57,"phases":4,"briefSummary":164,"conditions":165,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":4},"100588245","study-on-cardiac-output-evaluation-based-on-wearable-monitoring-data-100588245","NCT06938893","Study on Cardiac Output Evaluation Based on Wearable Monitoring Data","Inclusion Criteria:\n\n* Over 18 years old\n* Left ventricular ejection fraction (Left ventricular ejection fraction, LVEF) \\\u003C 50%(200 subjects)\n* Left ventricular ejection fraction (Left ventricular ejection fraction, LVEF) ≥50% (100 subjects)\n* Able to use smart phones and operate wearable devices such as wristbands\u002Fwatches\n\nExclusion Criteria:\n\n* Patients with pacemaker implantation\n* No smartphone\n* Currently participating in other clinical trials\n* Lactating women\n* Pregnant Women\n* Unable to run and ride due to personal physical and external reasons (subjects participating in the exercise state cardiac output model study)\n* Physical examination results in the past year have clear cardiovascular, metabolic, bone and joint related diseases that have exercise risk, or have diseases and related potential health risks confirmed by the self-examination form of physical status before exercise (participants in the exercise state cardiac output model study)\n* No informed consent was obtained",true,{"count":162,"type":19},300,"1 Month","Based on the monitoring data of wearable devices, with cardiac output (CO) as the gold standard, this study intends to develop a non-invasive evaluation model of CO based on wearable data, and optimize the parameters to realize the cardiac capacity detection function in resting and exercise states on the wearable device.",[166],"Cardiac Output","2025-04-14",{"date":169,"type":39},"2025-04-22",{"date":171,"type":19},"2025-04-20",{"date":173,"type":19},"2026-12-31",{"name":45,"class":46},{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":15,"minAge":75,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":20,"phases":184,"briefSummary":185,"conditions":186,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":4},"100573331","phase-2-sil-as-maintenance-therapy-in-multiple-myeloma-100573331","NCT06744894","SIL as Maintenance Therapy in Multiple Myeloma","Selinexor Combined With Ixazomib and Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma","Inclusion Criteria:\n\n* Pathologically confirmed Multiple Myeloma according World Health Organization (WHO) classification;\n* Patient is ≥ 18 years of age at the time of signing the informed consent form (ICF).\n* Patient must understand and voluntarily sign an ICF prior to any study-specific assessments\u002Fprocedures being conducted;\n* Patient is willing and able to adhere to the study visit schedule and other protocol requirements;\n* Documented response to ASCT (PR, VGPR, CR\u002Fstringent complete response \\[sCR\\]) according to IMWG criteria.\n\nExclusion Criteria:\n\n* Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment.\n* Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy.\n* Pregnant or lactating women",{"count":183,"type":19},50,[79],"The goal of this phase 2 trial is to test the safety and efficacy of selinexor combined with ixazomib and lenalidomide as maintenance therapy in patients with multiple myeloma.",[187],"Multiple Myeloma","2024-12-17",{"date":190,"type":39},"2024-12-20",{"date":192,"type":19},"2025-01-01",{"date":194,"type":19},"2030-01-01",{"name":45,"class":46},{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":203,"targetDuration":4,"studyType":20,"phases":205,"briefSummary":207,"conditions":208,"keywords":4,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":47},"100529611","phase-1-azacytidine-plus-caold-regimen-in-relapsedrefractory-peripheral-t-cell-lymphomas-100529611","NCT06176027","Azacytidine Plus CAOLD Regimen in Relapsed\u002FRefractory Peripheral T-Cell Lymphomas","Therapeutic Effect of Chemotherapy Azacytidine Plus CAOLD Regimen on Patients With Relapsed\u002FRefractory Peripheral T-Cell Lymphomas","Inclusion Criteria:\n\nPatients must satisfy all following criteria to be enrolled in the study:\n\n* Pathologically confirmed angioimmunoblastic T-cell lymphoma according World Health Organization (WHO) classification;\n* Patient is ≥ 18 years of age at the time of signing the informed consent form (ICF).\n* Patient must understand and voluntarily sign an ICF prior to any study-specific assessments\u002Fprocedures being conducted;\n* Patient is willing and able to adhere to the study visit schedule and other protocol requirements;\n* Relapsed (after partial or complete response) or refractory AITL after at least one line of systemic therapy (there is no mandatory resting period after the previous treatment as long as the biochemistry and hematology labs meet the inclusion criteria as below.)\n* Meet the following lab criteria:\n\n  * Absolute Neutrophil Count (ANC) ≥ 1,5 x 10\\^9\u002FL (≥ 1 x 10\\^9\u002FL if bone marrow (BM) involvement by lymphoma)\n  * Platelet ≥ 75 x 10\\^9\u002FL (≥ 50 x 10\\^9\u002FL if BM involvement by lymphoma)\n  * Hemoglobin ≥ 8 g\u002FdL.\n* Anticipated life expectancy at least 3 months\n\nExclusion Criteria:\n\n* Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment;\n* Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy;\n* Pregnant or lactating women",{"count":204,"type":19},52,[206,79],"PHASE1","This is a multicenter prospective single arm phase II study. The purpose of this study is to evaluate the safety and efficiency of azacytidine combined with CAOLD Regimen in the treatment of relapsed\u002Frefractory peripheral t-cell lymphomas.",[209,210],"Relapsed Peripheral T-Cell Lymphomas","Refractory Peripheral T-Cell Lymphomas","2024-10-26",{"date":213,"type":39},"2024-10-29",{"date":215,"type":39},"2024-10-01",{"date":217,"type":19},"2030-09-01",{"name":45,"class":46},{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":4,"eligibilityCriteria":225,"healthyVolunteers":11,"sex":15,"minAge":226,"maxAge":4,"enrollmentInfo":227,"targetDuration":4,"studyType":20,"phases":229,"briefSummary":230,"conditions":231,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":4},"100562070","phase-2-va-as-maintenance-therapy-post-allo-hsct-in-mds-and-aml-100562070","NCT06598384","VA as Maintenance Therapy Post Allo-HSCT in MDS and AML","Venetoclax Combined With Azacytidine as Maintenance Therapy Post Allogeneic Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndromes and Acute Myeloid Leukemia","Inclusion Criteria:\n\n* The patient should, in the investigator's opinion, be able to meet all clinical trial requirements.\n* The patient is willing and able to adhere to the study visit schedule and other protocol requirements.\n* Patients aged ≥18 years with a diagnosis of MDS or AML according to World Health Organization criteria (WHO) who had undergone alloSCT with myeloablative or reduced-intensity conditioning regimens were eligible. Related and unrelated donors were permitted.\n* Patients should be in morphologic complete remission (CR; ie, ≤5% bone marrow blasts) with absolute neutrophil counts ≥1.0×10\\^9 \u002FL and platelets ≥ 75×10\\^ 9 \u002FL before treatment.\n\nExclusion Criteria:\n\n* Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment.\n* Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy.\n* Pregnant or lactating women.","16 Years",{"count":228,"type":19},40,[79],"The goal of this phase 2 trial is to test the safety and efficacy of Venetoclax combined with Azacytidine as Maintenance Therapy post Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndromes and Acute Myeloid Leukemia.",[232],"Acute Myeloid Leukemia","2024-09-28",{"date":215,"type":39},{"date":236,"type":19},"2024-09",{"date":238,"type":19},"2030-09",{"name":45,"class":46},{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":11,"sex":15,"minAge":247,"maxAge":4,"enrollmentInfo":248,"targetDuration":4,"studyType":20,"phases":250,"briefSummary":251,"conditions":252,"keywords":4,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":254,"startDateStruct":255,"completionDateStruct":256,"leadSponsor":257,"locationsCount":47},"100552350","phase-1-va-conditioning-regimen-allo-hsct-for-elderly-higher-risk-mds-100552350","NCT06471946","VA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDS","Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT for Elderly Patients With Higher-risk Myelodysplastic Syndromes","Inclusion Criteria:\n\n* The patient should, in the investigator's opinion, be able to meet all clinical trial requirements.\n* The patient is willing and able to adhere to the study visit schedule and other protocol requirements.\n* The patient should be diagnosed with higher risk MDS according to the standard criteria of the World Health Organization (WHO).\n\nExclusion Criteria:\n\n* Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment.\n* Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy.","70 Years",{"count":249,"type":19},54,[206,79],"The goal of this phase 1\u002F2 trial is to test the safety and efficacy of Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT in treating patients with higher-risk MDS.",[253],"Higher-risk Myelodysplastic Syndromes",{"date":215,"type":39},{"date":215,"type":19},{"date":217,"type":19},{"name":45,"class":46},{"id":259,"slug":260,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":11,"sex":15,"minAge":75,"maxAge":4,"enrollmentInfo":265,"targetDuration":4,"studyType":20,"phases":267,"briefSummary":268,"conditions":269,"keywords":4,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":47},"100554759","phase-2-zanubrutinib-and-lenalidomide-as-maintenance-therapy-in-dlbcl-100554759","NCT06503263","Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL","Zanubrutinib and Lenalidomide as Maintenance Therapy in Patients With Diffuse Large B-cell Lymphoma","Inclusion Criteria:\n\n* Pathologically confirmed Diffuse Large B Cell Lymphoma according World Health Organization (WHO) classification;\n* Patient is ≥ 18 years of age at the time of signing the informed consent form (ICF).\n* Patient must understand and voluntarily sign an ICF prior to any study-specific assessments\u002Fprocedures being conducted;\n* Patient is willing and able to adhere to the study visit schedule and other protocol requirements;\n* Patient has recieved complete remission and has completed planed courses of chemotherapy\n* Meet the following lab criteria: Absolute Neutrophil Count (ANC) ≥ 1,5 x 10\\^9\u002FL (≥ 1 x 10\\^9\u002FL if bone marrow (BM) involvement by lymphoma)；Platelet ≥ 75 x 10\\^9\u002FL (≥ 50 x 10\\^9\u002FL if BM involvement by lymphoma)； Hemoglobin ≥ 8 g\u002FdL. Anticipated life expectancy at least 3 months\n\nExclusion Criteria:\n\n* Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment;\n* Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy;\n* Pregnant or lactating women",{"count":266,"type":19},240,[79],"The goal of this phase 2 trial is to test the safety and efficacy of zanubrutinib and lenalidomide as maintenance therapy in patients with DLBCL.",[121],"2024-09-05",{"date":272,"type":39},"2024-09-19",{"date":274,"type":39},"2024-08-30",{"date":276,"type":19},"2030-12-30",{"name":45,"class":46},{"id":279,"slug":280,"hasResults":11,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":4,"eligibilityCriteria":284,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":285,"targetDuration":4,"studyType":20,"phases":287,"briefSummary":288,"conditions":289,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":47},"100552265","phase-2-chg-combined-with-venetoclax-and-azacytidine-in-newly-diagnosed-aml-100552265","NCT06470841","CHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AML","CHG Regimen Combined With Venetoclax and Azacytidine in Newly Diagnosed Acute Myeloid Leukemia","Inclusion Criteria:\n\n* The patient should, in the investigator's opinion, be able to meet all clinical trial requirements.\n* The patient is willing and able to adhere to the study visit schedule and other protocol requirements.\n* The patient should be diagnosed with AML according to the standard criteria of the World Health Organisation (WHO).\n* The patient should not have received any prior treatment for AML.\n\nExclusion Criteria:\n\n* Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment.\n* Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy.\n* Pregnant or lactating women.",{"count":286,"type":19},85,[79],"The goal of this phase 2 trial is to test the safety and efficacy of CHG Combined With Venetoclax in treating patients with newly diagnosed AML.",[232],"2024-08-21",{"date":292,"type":39},"2024-08-22",{"date":294,"type":19},"2024-09-20",{"date":296,"type":19},"2028-12",{"name":45,"class":46},{"id":299,"slug":300,"hasResults":11,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":4,"eligibilityCriteria":304,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":305,"enrollmentInfo":306,"targetDuration":4,"studyType":20,"phases":308,"briefSummary":309,"conditions":310,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":47},"100553841","effect-of-aerobic-interval-training-on-atrial-fibrillation-burden-100553841","NCT06491329","Effect of Aerobic Interval Training on Atrial Fibrillation Burden","Effect of Aerobic Interval Training on Atrial Fibrillation Burden：A Multicenter Randomized Controlled Study","Inclusion Criteria:\n\n1. Age range: 18-74 years;\n2. Patients with non-permanent atrial fibrillation;\n3. Resting heart rate ≤110 beats\u002Fmin;\n4. No history of receiving a formal exercise prescription within the past six months;\n5. Willing to participate in this study, provide written informed consent, and agree to comply with follow-up procedures.\n\nExclusion Criteria:\n\n1. History of myocardial infarction, endocarditis\u002Fmyocarditis\u002Fpericarditis, stroke (ischemic\u002Fhemorrhagic), pulmonary embolism, lower extremity venous thrombosis, or cardiac surgery within the past 6 months;\n2. Moderate to severe pulmonary arterial hypertension, moderate to severe valvular heart disease, hypertrophic cardiomyopathy, aortic stenosis\u002Fdilation\u002Fdissection\u002Fintramural hematoma, congenital heart disease;\n3. Heart failure (NYHA class III-IV) or acute exacerbation of heart failure within the past 3 months;\n4. Unstable angina or severe coronary artery disease without revascularization;\n5. Concurrent severe arrhythmias\n\n   * frequent multifocal premature ventricular contractions\n   * ventricular tachycardia, ventricular fibrillation\n   * high-degree or complete atrioventricular block\n   * ventricular asystole lasting more than 5 seconds\n6. Uncontrolled hypertension or hypotension;\n7. Severe renal or hepatic dysfunction\n\n   * Stage 5 chronic kidney disease, defined as glomerular filtration rate \\\u003C15 ml\u002F(min•1.73 m2) or requiring dialysis;\n   * Patient with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels greater than or equal to 5 times the upper limit of normal as defined by the center during screening;\n8. Hypoxemia or severe lung disease;\n9. Lower extremity arterial stenosis or musculoskeletal disease preventing exercise training;\n10. Intracardiac thrombus;\n11. Pregnancy;\n12. Cognitive impairment preventing study cooperation;\n13. Severe anemia, infection, electrolyte disturbances, hyperthyroidism;\n14. Planned atrial fibrillation ablation during the study period;\n15. Post-implantation of pacemaker or ICD;\n16. Inability to use smart devices;\n17. Concurrent cancer or autoimmune or systemic inflammatory disease;\n18. Regular moderate-to-high intensity exercise habits (≥2 sessions of high-intensity endurance training per week or ≥3 sessions of moderate-intensity endurance training","74 Years",{"count":307,"type":19},156,[22],"Atrial fibrillation is the most common arrhythmia, with an increasing incidence and prevalence, significantly increasing the risk of death, stroke, heart failure, cognitive impairment, and dementia, severely impacting the quality of life for patients and burdening society and healthcare systems. In recent years, exercise-based cardiac rehabilitation has gradually become a new approach for the treatment of patients with heart disease. The main research topics include: 1. Changes in atrial fibrillation burden in non-permanent atrial fibrillation patients after 12 weeks of HIIT(high-intensity interval training ) or MIIT (moderate-intensity interval training). 2. Changes in cardiorespiratory fitness, quality of life scores, mental health assessment scores, atrial strain, and left ventricular diastolic function in non-permanent atrial fibrillation patients after 12 weeks of aerobic interval training, along with follow-up on the occurrence of exercise-related adverse events and adverse cardiovascular events during the study period.",[29,311],"Cardiac Rehabilitation","2024-08-01",{"date":314,"type":39},"2024-08-02",{"date":316,"type":19},"2024-08-15",{"date":318,"type":19},"2028-07-30",{"name":45,"class":46},{"id":321,"slug":322,"hasResults":11,"nctId":323,"briefTitle":324,"officialTitle":325,"acronym":326,"eligibilityCriteria":327,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":328,"targetDuration":4,"studyType":20,"phases":330,"briefSummary":331,"conditions":332,"keywords":334,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":337,"lastUpdatePostDateStruct":338,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":47},"100543013","smart-technology-facilitated-patient-centered-venous-thromboembolism-management-100543013","NCT06350344","Smart Technology Facilitated Patient-centered Venous Thromboembolism Management","Smart Technology Facilitated Patient-centered Venous Thromboembolism Management: A Multicenter Cohort Study","SmaVTE-COR","Inclusion Criteria:\n\n* Inpatients ≥18 years of age at admission;\n* At high-risk of VTE at discharge: Padua score ≥4 for medical patients and Caprini score ≥5 for surgical patients;\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Diagnosis of VTE at discharge;\n* Mental disorder or combination of other serious diseases leading to incapacity for independent living;\n* Inability to use smartphones, computer tablets and other smart devices;\n* Being pregnant or breastfeeding;\n* Have participated in similar trials or are undergoing other clinical trials.",{"count":329,"type":19},2353,[22],"Smart technologies, such as wearable devices, mobile technologies, and artificial intelligence, are being investigated for use in health management. These technologies have the potential to be applied in disease pre-warning, decision-making support, health education, and healthcare maintenance. They are expected to address the challenges in managing thrombosis, improve access to high-quality medical resources in various regions, and enhance the development of a network for thrombosis rescue and treatment prevention.\n\nThe objective of this study is to observe the long-term effect of mobile venous thromboembolism application (mVTEA) based patient-centered management of venous thromboembolism (VTE) on thromboprophylaxis, and establish a foundation of evidence for managing patients with high-risk VTE.",[143,33,333],"Health Education",[143,335,336,333],"Mobile Health","Prophylaxis","2024-07-15",{"date":339,"type":39},"2024-07-17",{"date":341,"type":19},"2024-11-01",{"date":343,"type":19},"2027-10-31",{"name":45,"class":46},{"id":346,"slug":347,"hasResults":11,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":4,"eligibilityCriteria":351,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":352,"targetDuration":4,"studyType":20,"phases":353,"briefSummary":354,"conditions":355,"keywords":4,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":364,"locationsCount":47},"100530690","phase-2-azacitidine-plus-pd-1-therapy-for-rr-hodgkin-lymphoma-100530690","NCT06190067","Azacitidine Plus PD-1 Therapy for R\u002FR Hodgkin Lymphoma","Azacitidine Plus PD-1 Therapy for Relapsed\u002FRefractory Hodgkin Lymphoma","Inclusion Criteria:\n\n* Pathologically confirmed Hodgkin Lymphoma according World Health Organization (WHO) classification.\n* Patient is ≥ 18 years of age at the time of signing the informed consent form (ICF).\n* Patient must understand and voluntarily sign an ICF prior to any study-specific assessments\u002Fprocedures being conducted.\n* Patient is willing and able to adhere to the study visit schedule and other protocol requirements.\n* Relapsed (after partial or complete response) or refractory AITL after at least one line of systemic therapy (there is no mandatory resting period after the previous treatment as long as the biochemistry and hematology labs meet the inclusion criteria as below).\n* Meet the following lab criteria: Absolute Neutrophil Count (ANC) ≥ 1,5 x 10\\^9\u002FL (≥ 1 x 10\\^9\u002FL if bone marrow (BM) involvement by lymphoma); Platelet ≥ 75 x 10\\^9\u002FL (≥ 50 x 10\\^9\u002FL if BM involvement by lymphoma); Hemoglobin ≥ 8 g\u002FdL.\n* Anticipated life expectancy at least 3 months.\n\nExclusion Criteria:\n\n* Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment.\n* Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy.\n* Pregnant or lactating women.",{"count":228,"type":19},[79],"The goal of this phase 2 trial is to test the safety and efficacy of azacitidine when given together with PD-1 therapy in treating patients with relapsed\u002Frefractory classic Hodgkin lymphoma.",[356,357],"Relapsed Classic Hodgkin Lymphoma","Refractory Classic Hodgkin Lymphoma","2024-01-28",{"date":360,"type":39},"2024-01-30",{"date":362,"type":39},"2023-10-30",{"date":296,"type":19},{"name":45,"class":46},{"id":366,"slug":367,"hasResults":11,"nctId":368,"briefTitle":369,"officialTitle":370,"acronym":4,"eligibilityCriteria":371,"healthyVolunteers":11,"sex":15,"minAge":372,"maxAge":373,"enrollmentInfo":374,"targetDuration":4,"studyType":20,"phases":376,"briefSummary":378,"conditions":379,"keywords":4,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":382,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":387,"locationsCount":47},"100273204","phase-2-therapeutic-effects-of-r-idaram-and-intrathecal-immunochemotherapy-on-elderly-patients-with-pcnsl-100273204","NCT02836158","Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL","Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With Primary CNS Lymphoma","Inclusion Criteria:\n\n* Newly diagnosed histologically proven non-Hodgkin's lymphoma (NHL).\n\nExclusion Criteria:\n\n* Involved sites other than the brain, meninges, CSF, or the eyes.\n* Age less than 18 years or greater than 75 years.\n* Inadequate bone marrow capacity (defined as neutrophils\\\u003C1.5 ×10\\^9\u002FL, platelets \\\u003C100 ×10\\^9\u002FL, and hemoglobin level\\\u003C 8 g\u002FdL).\n* Known cause of immunosuppression (ie, HIV type I infection).\n* Any previous malignancy.\n* Creatinine clearance below 60 mL\u002Fmin.\n* Heart insufficiency (NYHA IIIB or IV).\n* Uncontrolled infection.\n* Noncompensated active pulmonary or liver disease.\n* Previously treated for PCNSL, except by corticosteroids.","60 Years","75 Years",{"count":375,"type":19},100,[79,377],"PHASE3","This study suggests that R-IDARAM combined with intrathecal immunochemotherapy may be high effective in elderly patients with primary central nervous system lymphoma (PCNSL).",[380],"Primary Central Nervous System Lymphoma","2020-09-08",{"date":383,"type":39},"2020-09-09",{"date":385,"type":4},"2010-09",{"date":128,"type":19},{"name":45,"class":46},{"id":389,"slug":390,"hasResults":11,"nctId":391,"briefTitle":392,"officialTitle":393,"acronym":4,"eligibilityCriteria":394,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":373,"enrollmentInfo":395,"targetDuration":4,"studyType":20,"phases":396,"briefSummary":397,"conditions":398,"keywords":4,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":399,"startDateStruct":400,"completionDateStruct":401,"leadSponsor":402,"locationsCount":47},"100259548","phase-2-treatment-of-pcnsl-with-r-idaram-and-intrathecal-immunochemotherapy-100259548","NCT02657785","Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy","Treatment of Primary CNS Lymphoma With Systemic R-IDARAM Chemotherapy and Intrathecal Immunochemotherapy","Inclusion criteria:\n\n* Newly diagnosed histologically proven non-Hodgkin's lymphoma (NHL).\n\nExclusion criteria:\n\n* Involved sites other than the brain, meninges, CSF, or the eyes.\n* Age less than 18 years or greater than 75 years.\n* Inadequate bone marrow capacity (defined as neutrophils\\\u003C1.5 ×10\\^9\u002FL, platelets \\\u003C100 ×10\\^9\u002FL, and hemoglobin level\\\u003C 8 g\u002FdL).\n* Known cause of immunosuppression (ie, HIV type I infection).\n* Any previous malignancy.\n* Creatinine clearance below 60 mL\u002Fmin.\n* Heart insufficiency (NYHA IIIB or IV).\n* Uncontrolled infection.\n* Noncompensated active pulmonary or liver disease.\n* Previously treated for PCNSL, except by corticosteroids.",{"count":375,"type":19},[79,377],"This study suggests that R-IDARAM combined with intrathecal immunochemotherapy may be high effective in primary central nervous system lymphoma (PCNSL) patients.",[380],{"date":383,"type":39},{"date":385,"type":4},{"date":128,"type":19},{"name":45,"class":46},{"id":404,"slug":405,"hasResults":11,"nctId":406,"briefTitle":407,"officialTitle":408,"acronym":4,"eligibilityCriteria":409,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":410,"enrollmentInfo":411,"targetDuration":4,"studyType":20,"phases":413,"briefSummary":414,"conditions":415,"keywords":4,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":417,"lastUpdatePostDateStruct":418,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":424,"locationsCount":47},"100279500","phase-2-therapeutic-effects-of-hydrogen-on-steroid-refractoryor-steroid-dependent-cgvhd-100279500","NCT02918188","Therapeutic Effects of Hydrogen on Steroid-refractory\u002For Steroid-dependent cGVHD","Therapeutic Effects of Hydrogen on Steroid-refractory\u002For Steroid-dependent Chronic Graft-versus-host-disease","Inclusion Criteria:\n\n* Written informed consent\n* Male\n* not pregnant female\n* patients \\\u003C65 years old\n* Diagnosis of cGVHD steroid refractory (no response after Prednisone ≥1mg\u002Fkg ) or steroid-dependent cGVHD (had an initial response followed by a cGVHD flare upon steroid taper)\n* Patient intolerant to steroid therapy\n\nExclusion Criteria:\n\n* Patients with stable disease, not well controlled by the current treatment\n* Pregnancy\n* HIV positive\n* Severe liver or renal impairment: serum creatinine \\>2.5 mg\u002Fdl; serum bilirubin\\>2.5 mg\u002Fdl (without evidence of hepatic cGVHD)\n* Uncontrolled malignancies including the persistence of the underlying malignancy before the Allogeneic Transplantation and the relapse of hematopoietic malignancy\n* Any other investigational agents administered within last four weeks\n* Cardiac insufficiency (\\>grade II, New York Heart Association classification)\n* Inability to comply with medical therapy or follow-up","65 Years",{"count":412,"type":19},21,[79],"This study suggested that hydrogen has a potential as an effective and safe therapeutic agent on cGVHD.",[416],"Chronic Graft-versus-host Disease","2020-07-17",{"date":419,"type":39},"2020-07-21",{"date":421,"type":4},"2016-01",{"date":423,"type":19},"2031-01",{"name":45,"class":46},{"id":426,"slug":427,"hasResults":11,"nctId":428,"briefTitle":429,"officialTitle":430,"acronym":4,"eligibilityCriteria":431,"healthyVolunteers":11,"sex":15,"minAge":372,"maxAge":432,"enrollmentInfo":433,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":435,"conditions":436,"keywords":4,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":445,"locationsCount":47},"100374600","ctdna-after-chemotherapy-in-elderly-patients-with-acute-leukemia-100374600","NCT04157569","CtDNA After Chemotherapy in Elderly Patients With Acute Leukemia","Monitoring Circulating Tumor DNA After Chemotherapy in Elderly Patients With Acute Leukemia","Inclusion Criteria:\n\n* Written informed consent\n* Male\n* not pregnant female\n* patients \\>=60 years old\n* Diagnosis of acute leukemia\n\nExclusion Criteria:\n\n* Pregnancy\n* HIV positive\n* patients \\>=100 years old","100 Years",{"count":434,"type":19},200,"This study will monitor CtDNA After Chemotherapy in Elderly Patients With AL",[437],"Acute Leukemia","2020-02-24",{"date":440,"type":39},"2020-02-25",{"date":442,"type":39},"2019-11-05",{"date":444,"type":19},"2029-12-31",{"name":45,"class":46},""]